HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume – Should You Buy?

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw an uptick in trading volume on Wednesday . Approximately 32,043 shares changed hands during trading, a decline of 29% from the previous session’s volume of 45,117 shares.The stock last traded at $12.0940 and had previously closed at $11.91.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a report on Thursday, May 28th. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Bank of America decreased their price objective on HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, The Goldman Sachs Group cut their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, HUTCHMED currently has an average rating of “Hold” and a consensus price target of $14.87.

HUTCHMED Stock Up 1.1%

The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.50. The company has a 50-day moving average of $11.57 and a 200 day moving average of $12.75.

HUTCHMED (NASDAQ:HCM) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.09). The business had revenue of $139.14 million during the quarter, compared to the consensus estimate of $304.16 million. Analysts anticipate that HUTCHMED will post 0.23 earnings per share for the current year.

Hedge Funds Weigh In On HUTCHMED

Several large investors have recently modified their holdings of HCM. Ameriprise Financial Inc. lifted its position in HUTCHMED by 4.7% in the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares during the last quarter. Bank of America Corp DE increased its position in HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after acquiring an additional 3,035 shares during the last quarter. Dimensional Fund Advisors LP increased its position in HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after acquiring an additional 5,538 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of HUTCHMED in the first quarter valued at $365,000. Finally, BNP Paribas Financial Markets raised its stake in shares of HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after acquiring an additional 4,116 shares during the period. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.